Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Soy Protein Safety Concerns Lack Human Adverse Effect Data - FDA

This article was originally published in The Tan Sheet

Executive Summary

Challenges to the safety of soy protein-containing foods failed to provide documented evidence of adverse effects in humans or any information "about actual levels of potentially harmful components or about threshold levels for adverse effects in humans," FDA says in its approved soy protein health claim.

You may also be interested in...



Soy Protein Heart Health Claim History: Approved In 1999

Editor's note: Tan Sheet editors nearly 20 year ago reported on FDA approving a health claim for soy protein and the reduced risk of coronary heart disease for use with dietary supplements and food products. As the Rose Sheet today reports FDA's proposal to revoke the approval, we republish here the approval article from Oct. 25, 1999.

Potassium, Hypertension/Stroke Risk Reduction Health Claim Cleared By FDA

Functional food manufacturers could look to create a new niche market following FDA's authorization of a high blood pressure and stroke risk-reduction health claim for foods high in potassium.

Potassium, Hypertension/Stroke Risk Reduction Health Claim Cleared By FDA

Functional food manufacturers could look to create a new niche market following FDA's authorization of a high blood pressure and stroke risk-reduction health claim for foods high in potassium.

Related Content

Topics

UsernamePublicRestriction

Register

PS090481

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel